Bromantane for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Bromantane for Health & Longevity

Created on 07/07/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Bromantane raises the brain's own dopamine-making capacity rather than forcing a surge, giving gentle stimulation and reduced anxiety without an obvious crash or dependence. Its most credible benefit is easing persistent fatigue paired with low mood and tension. The evidence is thin, single-country, and conflicted; long-term safety is unknown and product quality varies. (Full Review)

Protocol

Dose
50–100 mg/day
Start at 50 mg; increase only if well tolerated
Timing
Morning
Before early afternoon; ~11 h half-life makes late dosing the main cause of insomnia
Course
Up to 28 days
Time-limited 2–4 week courses cycled with breaks, not open-ended use
Time to effect
Onset
~3 days
Anti-fatigue benefits begin
Full effect
1–4 weeks
Benefits build over the course
Persistence
~1 month
Benefit lingers after a course stops

Benefits

Contraindications
  • Schizophrenia, other psychotic disorders, or bipolar disorder
  • Uncontrolled hypertension (persistently above ~160/100 mmHg) or unstable cardiovascular disease
  • Pregnancy or breastfeeding
  • Competitive athletes subject to anti-doping rules
    •
Key Interactions
  • Dopaminergic drugs (levodopa, pramipexole, ropinirole)
  • MAOIs (phenelzine, selegiline, moclobemide)
  • Other stimulants and stimulant nootropics (amphetamine, methylphenidate, modafinil)
  • Antipsychotics and dopamine antagonists (haloperidol, risperidone, metoclopramide)
  • OTC stimulants and decongestants (pseudoephedrine, phenylephrine, high-dose caffeine)
  • Dopamine-precursor supplements (L-tyrosine, L-DOPA from Mucuna pruriens)
  • Other activating supplements (rhodiola, high-dose green tea/caffeine, forskolin)
    •

Risk & Side Effects

  • Medium: Limited long-term and independent safety data; overstimulation, insomnia, and irritability
    •
  • Low: Headache and dry mouth; product adulteration and dosing errors from unregulated sourcing
    •
  • Speculative: Dopaminergic effects in psychosis-prone individuals; reproductive and developmental effects
    •

Monitoring

Marker Target Why
Blood pressure ~110–125 / 70–80 mmHg Detect any stimulant-type rise
Resting heart rate 55–70 bpm Screen for overstimulation
ALT / AST (liver enzymes) ALT ~10–26 U/L; AST ~10–26 U/L Screen liver stress given poorly characterized metabolism
Fasting glucose 75–86 mg/dL General metabolic baseline
Complete blood count (CBC) Within functional reference range General safety baseline for repeated courses
Prolactin (optional) Low-normal for sex Plausibility check on dopaminergic effect

Cadence: Baseline, then once mid-course (~1–2 weeks) and after any dose increase, then before any subsequent course

Qualitative Assessment

  • Energy and daytime fatigue
  • Motivation and drive
  • Sleep quality and time to fall asleep
  • Anxiety and stress reactivity
  • Cognitive clarity and focus under load
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.